Neuropathic Pain Drug Market (Painful Diabetic Neuropathy, Postherpetic and Trigeminal Neuralgia) Forecast to 2022 in New Report Available at MarketOptimizer.org


Dallas, Texas (PRWEB) September 26, 2014 -- With seven promising neuropathic pain (NP) treatments expected to be launched in the coming years, the NP therapeutics market value - covering painful diabetic neuropathy, postherpetic neuralgia and trigeminal neuralgia - is forecast to increase from $2.58 billion in 2012 to $3.53 billion by 2022, at a Compound Annual Growth Rate (CAGR) of 3.19%. According to MarketOptimizer.org's latest report “PharmaPoint: Neuropathic Pain - Global Drug Forecast and Market Analysis to 2022”, seven novel pipeline drugs targeting these three indications will enter the market before 2022. These include Daiichi Sankyo’s DS-5565, Convergence’s CNV-2197944, Grünenthal’s Cebranopadol and Impax’s Eladur. The sales of these pipeline therapies to account for 23.8% of the global NP market by 2022.

This report provides an overview of three neuropathic pain indications - painful diabetic neuropathy, postherpetic neuralgia and trigeminal neuralgia - including epidemiology, etiology, pathophysiology, symptoms, diagnosis, and treatment guidelines. It also gives annualized neuropathic pain therapeutics market revenue, annual cost of therapy and treatment usage pattern data from 2012 to 2022.


Key Questions Answered

• The neuropathic pain market is marked by the presence of a number of unmet needs in current treatments. What are the main unmet needs in this market? Will the drugs under development fulfil the unmet needs of the neuropathic pain market?
• What differences exist in the current disease management across the 3 NP indications, and across the 7 markets?
• What are the views of KOLs on the present and future landscape of the neuropathic pain market?
• Several brands of neuropathic pain drugs are due for patent expiry. How will the patent expiries impact the neuropathic pain therapeutics market?
• The developmental pipeline consists of several novel drugs. Which of these drugs will attain high sales revenues during 2012-2022?

Key Findings

• The main driver for the expansion of the NP market will be the increasing NP incidence due to 2 main reasons: the growing elderly population
• And the increase in the prevalence and diagnosis of type 2 diabetes which will lead to growth of the painful diabetic neuropathy (PDN) market - the largest NP segment.
• Additionally, the approval of novel formulations and first-in-class therapies in pipeline for NP that will drive sales in this market
• The greatest barrier to growth in this market will be the fact that the key market leading drugs will go off patent during the forecast period leading to a NP market largely dominated by generics, which raises the barrier to entry for novel drug therapies.

Order a Purchase Copy @ http://www.marketoptimizer.org/contacts/purchase?rname=10714.

Company Profiles include in Report:
• Pfizer
• Eli Lilly
• Grünenthal
• Endo Health Solutions
• Janssen Pharmaceuticals
• Daiichi Sankyo
• Convergence Pharmaceuticals

Scope
• Overview of 3 neuropathic pain indications - painful diabetic neuropathy, Postherpetic neuralgia and trigeminal neuralgia, including epidemiology, etiology, pathophysiology, symptoms, diagnosis, and treatment guidelines.
• Annualized neuropathic pain therapeutics market revenue, annual cost of therapy and treatment usage pattern data from 2012 and forecast for 10 years to 2022.
• Key topics covered include strategic competitor assessment, market characterization, unmet needs, clinical trial mapping and implications for the neuropathic pain therapeutics market.
• Pipeline analysis: focus on mid to late-stage pipeline drugs discussing emerging trends as well as overview of earlier phase drugs.
• Analysis of the current and future market competition in the global neuropathic pain therapeutics market. Insightful review of the key industry drivers, restraints and challenges. Each trend is independently researched to provide qualitative analysis of its implications.

Inquire for Discount @ http://www.marketoptimizer.org/contacts/discount?rname=10714.
(This is a premium report priced at US$10995 for a single user License.)

Reasons to buy
• Develop and design in-licensing and out-licensing strategies through a review of pipeline products and technologies, and by identifying the companies with the most robust pipeline. Additionally a list of acquisition targets included in the pipeline product company list.
• Develop business strategies by understanding the trends shaping and driving the global neuropathic pain therapeutics market.
• Drive revenues by understanding the key trends, innovative products and technologies, market segments, and companies likely to impact the global neuropathic pain therapeutics market in future.
• Formulate effective sales and marketing strategies by understanding the competitive landscape and by analyzing the performance of various competitors.
• Identify emerging players with potentially strong product portfolios and create effective counter-strategies to gain a competitive advantage.
• Track drug sales in the global neuropathic pain therapeutics market from 2012-2022.

About Us:
MarketOptimizer.org is an online database of market research reports offer in-depth analysis of over 5000 market segments. The library has syndicated reports by leading market research publishers across the globe and also offer customized market research reports for multiple industries.

If you have any questions regarding information in these press releases please contact the company listed in the press release. Our complete disclaimer appears [here](http://www.marketoptimizer.org).
Contact Information
Ritesh Tiwari
Market Optimizer
http://www.marketoptimizer.org/
+1 (888) 391-5441

Online Web 2.0 Version
You can read the online version of this press release here.